Clinical summary
Summary
Participants in this trial will receive Venetoclax via oral administration, starting with a 20mg dose once daily (QD). Dose escalation will occur weekly in the following progression: 50mg QD, 100mg QD, 200mg QD, 400mg QD, as tolerated.Conditions
This trial is treating patients with Chronic Lymphocytic Leukaemia (CLL).
Cancer
Blood
Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
AbbVie
Scientific Title
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion